SELLAS Life Sciences

SELLAS Life Sciences Group is a United States biopharmaceutical company focused on the development of oncology medicines, including cancer immunotherapies and other investigational treatments. The company’s present corporate identity emerged from the December 2017 all-stock combination between privately held Sellas Life Sciences Group Ltd. and the publicly traded oncology company Galena Biopharma, Inc. The transaction used Galena as the public-company vehicle and resulted in the renamed Sellas Life Sciences Group, Inc., which traded on Nasdaq under the symbol SLS. The company’s history is therefore closely connected with the predecessor businesses that supplied its corporate structure and oncology portfolio. Galena originated from the cancer-therapy activities of RXi Pharmaceuticals Corporation, an enterprise that had earlier been associated with CytRx and RNA-interference research. In 2011, RXi separated its oncology division, which became Galena Biopharma. Galena acquired Apthera and its NeuVax program that year, later expanded its portfolio through the acquisition of Mills Pharmaceuticals, and developed additional cancer-related programs. It also commercialized Abstral Sublingual, an analgesic for breakthrough cancer pain, beginning in 2013. The inherited development portfolio included NeuVax, also known as nelipepimut-S, an investigational breast-cancer immunotherapy intended to stimulate an immune response against tumor cells. Galena studied NeuVax alone and in combination with trastuzumab, marketed by Genentech as Herceptin, and pursued clinical development in breast cancer. Other programs associated with the predecessor included GALE-301 and GALE-302, investigational immunotherapies for ovarian and breast cancers, and GALE-401, a controlled-release formulation of anagrelide investigated for essential thrombocythemia. These programs were at different stages of development and should not be treated as approved SELLAS products. SELLAS is best understood as a development-stage oncology company rather than a broad consumer pharmaceutical brand. Its operating model centers on research, clinical development, regulatory advancement, licensing or partnering possibilities, and the eventual commercialization of successful therapies. Publicly available material supplied for this entry does not establish a complete current product-commercialization list, current headquarters, current executive roster, or a definitive description of all active clinical programs. The company’s website is the principal corporate reference for current information. The predecessor’s history also includes substantial governance and securities-market controversy. In 2014, Galena acknowledged a relationship with stock-promotion firms after reporting and investigative coverage alleged that promotional articles had not adequately disclosed their financial connections to the company. The matter led to investor litigation, disclosure of an SEC investigation, and broader regulatory scrutiny of promotional practices involving several biotechnology companies. These events belong primarily to Galena’s pre-merger history, but they remain relevant to the corporate lineage of the public company that became SELLAS. SELLAS’s positioning is consequently defined by specialized oncology research, with emphasis on immune-based approaches and novel treatments for serious diseases. Its brand is associated more with clinical-stage scientific development and public-market biotechnology than with a mature portfolio of widely distributed medicines. Any assessment of current pipeline status, approvals, partnerships, leadership, or financial performance should be checked against the company’s latest filings and corporate disclosures.

SELLAS Life Sciences Group’s corporate lineage combines the privately held Sellas oncology business with Galena Biopharma, the publicly traded predecessor that provided the transaction vehicle. Before Galena existed, Argonaut Pharmaceuticals changed its name to RXi Pharmaceuticals Corporation in November 2006. RXi was associated with CytRx and pursued RNA-interference technologies, including a 2007 licensing arrangement with TriLink Biotechnologies. The company went public on Nasdaq in March 2008 under the symbol RXII, with CytRx retaining a significant ownership interest. RXi also received private financing and National Institutes of Health support during its early development period. In March 2011, RXi announced plans to acquire Arizona-based Apthera for approximately $7 million. The transaction brought the NeuVax breast-cancer immunotherapy into the company’s portfolio. Later that year, RXi separated its cancer-therapy division. The oncology business was renamed Galena Biopharma and moved to Lake Oswego, Oregon, while RXi retained the RNA-interference activities. Galena subsequently developed a portfolio of oncology programs and sought partnerships for combination treatments. In November 2011, it announced work with Genentech involving NeuVax and Herceptin, with the combination studied in clinical development for breast cancer. Galena expanded its corporate and product activities during the following years. It acquired Mills Pharmaceuticals in January 2014 and moved its headquarters to Portland in April of that year. The company began selling Abstral Sublingual, a cancer-pain analgesic, in 2013. It also pursued GALE-301 and GALE-302, described as investigational immunotherapies for ovarian and breast cancers, and advanced GALE-401, a controlled-release anagrelide program for essential thrombocythemia. The development status of these programs changed over time, and the historical descriptions do not establish that they became approved or currently marketed SELLAS products. Galena’s corporate history was severely affected by securities-market controversy. In late 2012, the company sued over an anonymous internet report that it characterized as false and manipulative. In February 2014, investigative coverage reported that Galena had paid MissionIR and the DreamTeam brand to promote its stock. The company’s share price declined after the disclosures, and additional reporting alleged undisclosed promotional relationships and insider selling. Galena later acknowledged the promotional relationship and reported that the SEC was investigating. Several shareholder lawsuits followed, alleging that misleading promotional articles had been used to support the stock price. The episode contributed to wider scrutiny of similar practices across the biotechnology sector, culminating in SEC enforcement actions announced in 2017. Leadership also changed during the predecessor period. Mark Ahn replaced Noah Beerman as Galena’s president and chief executive in 2011. Ahn resigned in August 2014 and was replaced by Mark Schwartz. Schwartz’s resignation became effective on January 31, 2017, when Galena also said it would explore strategic alternatives. In 2015, the company moved its headquarters to San Ramon, California. In 2017, Galena announced an all-stock merger with privately held Sellas Life Sciences Group Ltd. The transaction closed on December 29, 2017, and Galena was renamed Sellas Life Sciences Group, Inc. The combined business focused on developing novel cancer treatments. The resulting company continued as a Nasdaq-listed public biotechnology enterprise under the symbol SLS. The available reference material does not provide a sufficiently complete account of later clinical milestones, current leadership, present headquarters, or the full status of the inherited programs; those details require verification from current company filings and official disclosures.

• 2017

  Sellas merger creates the current public company

  [1]Galena Biopharmaen.wikipedia.org

  Galena completed an all-stock combination with Sellas Life Sciences Group Ltd. and adopted the Sellas Life Sciences Group name.

• 2014

  Promotional-practices controversy becomes public

  [1]Galena Biopharmaen.wikipedia.org

  Reporting exposed Galena’s relationship with stock-promotion firms, followed by company disclosures, investor lawsuits, and SEC scrutiny.

• 2013

  Abstral commercialization begins

  [1]Galena Biopharmaen.wikipedia.org

  Galena began selling Abstral Sublingual, an analgesic for cancer pain.

• 2011

  Apthera acquisition and oncology separation

  [1]Galena Biopharmaen.wikipedia.org

  RXi planned the acquisition of Apthera, bringing NeuVax into the portfolio, and later separated its cancer-therapy division as Galena Biopharma.

• 2008

  RXi begins Nasdaq trading

  [1]Galena Biopharmaen.wikipedia.org

  RXi Pharmaceuticals began trading publicly on Nasdaq under the ticker RXII.

• 2006

  Argonaut Pharmaceuticals becomes RXi Pharmaceuticals

  [1]Galena Biopharmaen.wikipedia.org

  Argonaut Pharmaceuticals changed its name to RXi Pharmaceuticals Corporation, an important predecessor in the company’s corporate lineage.

A clinical-stage biopharmaceutical company centered on oncology research, cancer immunotherapy, and the development of treatments for serious diseases.

• Investigational cancer immunotherapy

  NeuVax (nelipepimut-S)

  NeuVax is an investigational peptide-based breast-cancer immunotherapy acquired through Galena’s 2011 Apthera transaction. The program was intended to stimulate an immune response against tumor-associated targets and was studied both as a standalone treatment and in combination with trastuzumab, marketed by Genentech as Herceptin. The supplied historical material describes clinical development but does not establish current approval or commercialization status.

• Cancer-pain analgesic · 2013

  Abstral Sublingual

  Abstral Sublingual was an analgesic product for breakthrough cancer pain and was identified as Galena’s first developed drug to reach commercial sale in 2013. It belongs to the predecessor company’s historical commercial portfolio rather than being confirmed here as a current SELLAS offering.

• Investigational cancer immunotherapy

  GALE-301

  GALE-301 was described in the predecessor-company material as an investigational immunotherapy program for ovarian cancer. The available reference identifies clinical-stage development but does not provide enough current information to confirm its present status, ownership, or clinical outcomes under SELLAS.

• Investigational cancer immunotherapy

  GALE-302

  GALE-302 was described as an investigational immunotherapy program for breast cancer. It was part of Galena’s oncology development portfolio, but the supplied sources do not establish whether the program remains active or forms part of SELLAS’s current pipeline.

• Investigational hematology treatment · 2016

  GALE-401

  GALE-401 was a controlled-release formulation of anagrelide investigated for essential thrombocythemia. Historical material states that the program was cleared by the FDA for Phase III clinical trials in December 2016. This entry does not imply that the product received marketing approval or remains in development.

• 2014

  Galena stock-promotion controversy

  Investigative reporting alleged that Galena paid MissionIR and the DreamTeam brand to promote its stock through articles whose financial relationship with the company was not adequately disclosed. Galena acknowledged the relationship and disclosed an SEC investigation. The disclosures were followed by a sharp share-price decline, shareholder lawsuits, and broader scrutiny of promotional practices in biotechnology. The controversy concerns the Galena predecessor but is relevant to the history of the public company that later became SELLAS.

  Source

Read more

• 2017

  All-stock combination with Sellas Life Sciences Group Ltd.M&A

  Background

  Galena was a public oncology company seeking strategic alternatives, while Sellas was a privately held oncology business.

  Action taken

  The companies completed an all-stock reverse-merger transaction, after which Galena was renamed Sellas Life Sciences Group, Inc.

  Aftermath

  The combined company focused on developing novel cancer treatments and traded on Nasdaq under SLS.

  Source

• 2011

  Planned acquisition of AptheraM&A

  Background

  RXi sought to expand into oncology by acquiring Arizona-based Apthera and its NeuVax breast-cancer program.

  Action taken

  The company announced a planned acquisition valued at approximately $7 million and subsequently incorporated the program into its oncology activities.

  Aftermath

  NeuVax became a central part of Galena’s historical development portfolio and was later studied in combination with Herceptin.

  Announced transaction value. $7 million (2011)

  Source

• 2011

  Separation of oncology operations into Galena BiopharmaStrategy

  Background

  RXi maintained RNA-interference activities while separating its cancer-therapy operations into a dedicated business.

  Action taken

  The cancer division was renamed Galena Biopharma and operated as a distinct oncology-focused company.

  Aftermath

  Galena became the corporate predecessor whose public listing was later used for the Sellas combination.

  Source

1. 1Galena Biopharmaen.wikipedia.org
2. 2SELLAS Life Sciences corporate websitesellaslifesciences.com